Safety and efficacy of transitioning inflammatory bowel disease patients from intravenous to subcutaneous infliximab: a single-center real-world experience

BACKGROUND: A new subcutaneous (SC) formulation exists for infliximab (CT-P13 SC). The aim of this study was to assess the durability of clinical and endoscopic responses after a switch from intravenous (IV) to SC infliximab. METHODS: Patients were transitioned on maintenance infliximab, including t...

Descripción completa

Detalles Bibliográficos
Autores principales: Jeffrey, Angus W., Abu-Rgeef, Reeham, Picardo, Sherman, Menon, Shankar, So, Kenji, Venugopal, Kannan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hellenic Society of Gastroenterology 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10433247/
https://www.ncbi.nlm.nih.gov/pubmed/37664232
http://dx.doi.org/10.20524/aog.2023.0816

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10433247/
https://www.ncbi.nlm.nih.gov/pubmed/37664232
http://dx.doi.org/10.20524/aog.2023.0816

Ejemplares similares